Genscript Biotech 경영진
경영진 기준 점검 3/4
Genscript Biotech CEO는 Sherry Shao, Jul2021 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 $2.81M, 14.4% 급여 및 85.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 HK$51.76M 가치에 해당하는 회사 주식의 0.073% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.1 년과 3.4 년입니다.
핵심 정보
Sherry Shao
최고경영자
US$2.8m
총 보수
| CEO 급여 비율 | 14.43% |
| CEO 재임 기간 | 5.1yrs |
| CEO 지분 보유율 | 0.07% |
| 경영진 평균 재임 기간 | 5.1yrs |
| 이사회 평균 재임 기간 | 3.4yrs |
최근 경영진 업데이트
Recent updates
분석 기사 • Aug 18
Genscript Biotech Corporation (HKG:1548) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$24.74
It's been a pretty great week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with its shares surging 15...
내러티브 업데이트 • Aug 17
1548: AI Drug Discovery Partnership Will Test Elevated Profit Assumptions
Analysts now place Genscript Biotech's fair value at about HK$20.21, compared with the prior HK$17.68, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple. What's in the News for Genscript Biotech GenScript Biotech and Tamarind Bio agreed a partnership that links Tamarind Bio's AI molecular design platform with GenScript's wet lab validation services, creating a connected validation engine for AI enabled drug discovery.내러티브 업데이트 • Jun 23
1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.내러티브 업데이트 • Jun 06
1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.내러티브 업데이트 • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).내러티브 업데이트 • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).내러티브 업데이트 • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
새로운 내러티브 • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 25
1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).내러티브 업데이트 • Mar 10
1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.내러티브 업데이트 • Feb 23
1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.내러티브 업데이트 • Feb 09
1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).분석 기사 • Nov 03
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...분석 기사 • Oct 10
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...분석 기사 • Sep 18
We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...분석 기사 • Sep 08
Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...내러티브 업데이트 • Aug 21
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.새로운 내러티브 • Jul 17
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$637m |
| Mar 31 2026 | n/a | n/a | -US$585m |
| Dec 31 2025 | US$3m | US$405k | -US$533m |
| Sep 30 2025 | n/a | n/a | -US$264m |
| Jun 30 2025 | n/a | n/a | US$5m |
| Mar 31 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$4m | US$352k | -US$67m |
| Jun 30 2024 | n/a | n/a | US$419m |
| Mar 31 2024 | n/a | n/a | US$421m |
| Dec 31 2023 | US$2m | US$353k | US$423m |
보상 대 시장: Sherry의 총 보수(USD2.81M)는 Hong Kong 시장에서 비슷한 규모 기업의 평균(USD911.71K)보다 높습니다.
보상과 수익: Sherry의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Sherry Shao (46 yo)
5.1yrs
재임 기간
US$2,807,000
보수
Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 11yrs | US$525.00k | 0.016% HK$ 11.7m | |
| CEO & COO | 5.1yrs | US$2.81m | 0.073% HK$ 51.8m | |
| Co-Founder | 24.6yrs | US$803.00k | 0.040% HK$ 28.3m | |
| Co-Founder & Executive Director | 3.7yrs | US$645.00k | 데이터 없음 | |
| Chief Strategy Officer & Executive Director | 5.8yrs | US$595.00k | 0.043% HK$ 30.8m | |
| Chief Financial Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| General Counsel & Chief Compliance Officer | no data | 데이터 없음 | 데이터 없음 | |
| Chief Marketing & Corporate Communications Officer | no data | 데이터 없음 | 데이터 없음 | |
| Head of Global Diversity | no data | 데이터 없음 | 데이터 없음 | |
| Head of Sustainability | no data | 데이터 없음 | 데이터 없음 | |
| President of GenScript Life Science Group | no data | 데이터 없음 | 데이터 없음 | |
| CEO of Probio | no data | 데이터 없음 | 데이터 없음 |
5.1yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 관리: 1548의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.1 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 11yrs | US$525.00k | 0.016% HK$ 11.7m | |
| Co-Founder | 11.3yrs | US$803.00k | 0.040% HK$ 28.3m | |
| Co-Founder & Executive Director | 4.3yrs | US$645.00k | 데이터 없음 | |
| Chief Strategy Officer & Executive Director | 5.8yrs | US$595.00k | 0.043% HK$ 30.8m | |
| Independent Non-executive Director | 1.9yrs | US$70.00k | 0.00030% HK$ 214.0k | |
| Member of Advisory Board | 2.6yrs | 데이터 없음 | 데이터 없음 | |
| Member of Advisory Board | 6.9yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 1.9yrs | US$100.00k | 데이터 없음 | |
| Member of Scientific Advisory Board | 2.4yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 7.8yrs | US$100.00k | 0.00068% HK$ 485.1k | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | 데이터 없음 | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | 데이터 없음 |
3.4yrs
평균 재임 기간
66yo
평균 나이
경험이 풍부한 이사회: 1548의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.4 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/24 20:58 |
| 종가 | 2026/08/24 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Genscript Biotech Corporation는 12명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |